Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

Sunstone

Sunstone

Headquartered in Copenhagen, Sunstone Capital is an early-stage Life Science and Technology venture capital company investing in European start-up companies with strong potential to achieve global success in their markets. Since our establishment in 2007, we have built a strong portfolio currently totaling 50 companies and have completed several successful trade sales and IPOs.

With approximately EUR 700 million in funds under management distributed on seven funds, Sunstone is today one of the leading and most active independent venture capital investors in the Nordic market.

Our limited partner investors currently include major Nordic and international institutional investors: European Investment Fund, Industriens Pension, Sampension, ATP, Nordea Liv og Pension, Vaekstfonden, and Dansk Vækstkapital.

Our origin – Vikings in the water
A sunstone is a gemstone that was used by the seafaring Vikings a thousand years ago as a navigational instrument to explore the world and find their way home again. Although probably not aware of it, the Nordic explorers and warriors were actually using advanced technology (downward wavelength conversion) to open up new markets and create new opportunities.

At Sunstone, we work with our companies to conquer the world and help them pave the road for a safe and prosperous return for our investors.

Sunstone’s Technology Ventures team invests in software, mobile and and internet companies with global potential.

Technology Ventures

Sunstone’s Life Science Ventures team invests in world-class companies in the areas of therapeutics, medical technology and diagnostics.

Life Science Ventures

A market driven investment strategy

Sunstone Life Science Ventures invests in early-stage Life Science companies in the therapeutic, medical technology and diagnostics fields. Our geographical scope is Europe with particular emphasis on the Nordic countries, Germany and Switzerland.

Our point of entry differs depending on the type of Life Science opportunity. In the therapeutic field, we invest when drug candidates are in the pre-clinical or clinical phase I.  In the areas of medical technology and diagnostics, we tend to invest in companies just before the pivotal clinical trials required to support the intended use and marketing claims.

Sunstone Life Science Ventures’ investment strategy has a strong industry focus vis-à-vis potential buyers of our portfolio companies. Since we believe that most exits in the Life Science sector will continue to take place in the M&A space, we prefer business models suitable for this exit route. To appear on potential acquirers’ radar screens, we invest in opportunities that have the potential of becoming either a threat or a complement to existing products on the market. We look out for opportunities which target unmet medical needs in commercially attractive markets, and we seek products which, once approved, are likely to receive attractive reimbursement and pricing structures. We have a preference for companies targeting niche markets. In the therapeutic area, opportunities aimed at specialty pharma and orphan drug indications are especially interesting, whereas we consider opportunities aimed at widespread diseases already addressed by established medical treatment regimes less interesting.

We believe that the single most important factor when developing a successful company is the quality of the management team. This is not the same as saying that we only invest in savvy entrepreneurs with a strong track record. But less experienced management teams should be open to change if needed to accelerate the company.

We are committed to working hands-on with our portfolio companies to build value. In most cases, Sunstone is represented on the board of directors and works closely with the management team and the board members to develop the company. Another unique offering aimed at building the value of our portfolio companies is Sunstone’s Business Development Board, established in 2007 and consisting of leading Life Science executives from Europe, the US, and Japan.

Headquartered in Copenhagen, Sunstone Capital is an early-stage Life Science and Technology venture capital company investing in European start-up companies with strong potential to achieve global success in their markets. Since our establishment in 2007, we have built a strong portfolio currently totaling 50 companies and have completed several successful trade sales and IPOs.

With approximately EUR 700 million in funds under management distributed on seven funds, Sunstone is today one of the leading and most active independent venture capital investors in the Nordic market.

Our limited partner investors currently include major Nordic and international institutional investors: European Investment Fund, Industriens Pension, Sampension, ATP, Nordea Liv og Pension, Vaekstfonden, and Dansk Vækstkapital.

Our origin – Vikings in the water
A sunstone is a gemstone that was used by the seafaring Vikings a thousand years ago as a navigational instrument to explore the world and find their way home again. Although probably not aware of it, the Nordic explorers and warriors were actually using advanced technology (downward wavelength conversion) to open up new markets and create new opportunities.

At Sunstone, we work with our companies to conquer the world and help them pave the road for a safe and prosperous return for our investors.

Sunstone’s Technology Ventures team invests in software, mobile and and internet companies with global potential.

Technology Ventures

Sunstone’s Life Science Ventures team invests in world-class companies in the areas of therapeutics, medical technology and diagnostics.

Life Science Ventures

A market driven investment strategy

Sunstone Life Science Ventures invests in early-stage Life Science companies in the therapeutic, medical technology and diagnostics fields. Our geographical scope is Europe with particular emphasis on the Nordic countries, Germany and Switzerland.

Our point of entry differs depending on the type of Life Science opportunity. In the therapeutic field, we invest when drug candidates are in the pre-clinical or clinical phase I.  In the areas of medical technology and diagnostics, we tend to invest in companies just before the pivotal clinical trials required to support the intended use and marketing claims.

Sunstone Life Science Ventures’ investment strategy has a strong industry focus vis-à-vis potential buyers of our portfolio companies. Since we believe that most exits in the Life Science sector will continue to take place in the M&A space, we prefer business models suitable for this exit route. To appear on potential acquirers’ radar screens, we invest in opportunities that have the potential of becoming either a threat or a complement to existing products on the market. We look out for opportunities which target unmet medical needs in commercially attractive markets, and we seek products which, once approved, are likely to receive attractive reimbursement and pricing structures. We have a preference for companies targeting niche markets. In the therapeutic area, opportunities aimed at specialty pharma and orphan drug indications are especially interesting, whereas we consider opportunities aimed at widespread diseases already addressed by established medical treatment regimes less interesting.

We believe that the single most important factor when developing a successful company is the quality of the management team. This is not the same as saying that we only invest in savvy entrepreneurs with a strong track record. But less experienced management teams should be open to change if needed to accelerate the company.

We are committed to working hands-on with our portfolio companies to build value. In most cases, Sunstone is represented on the board of directors and works closely with the management team and the board members to develop the company. Another unique offering aimed at building the value of our portfolio companies is Sunstone’s Business Development Board, established in 2007 and consisting of leading Life Science executives from Europe, the US, and Japan.

Annual & quarterly reports
Sunstone's logo

Sunstone

Headquartered in Copenhagen, Sunstone Capital is an early-stage Life Science and Technology venture capital company investing in European start-up companies with strong potential to achieve global success in their markets. Since our establishment in 2007, we have built a strong portfolio currently totaling 50 companies and have completed several successful trade sales and IPOs.

With approximately EUR 700 million in funds under management distributed on seven funds, Sunstone is today one of the leading and most active independent venture capital investors in the Nordic market.

Our limited partner investors currently include major Nordic and international institutional investors: European Investment Fund, Industriens Pension, Sampension, ATP, Nordea Liv og Pension, Vaekstfonden, and Dansk Vækstkapital.

Our origin – Vikings in the water
A sunstone is a gemstone that was used by the seafaring Vikings a thousand years ago as a navigational instrument to explore the world and find their way home again. Although probably not aware of it, the Nordic explorers and warriors were actually using advanced technology (downward wavelength conversion) to open up new markets and create new opportunities.

At Sunstone, we work with our companies to conquer the world and help them pave the road for a safe and prosperous return for our investors.

Sunstone’s Technology Ventures team invests in software, mobile and and internet companies with global potential.

Technology Ventures

Sunstone’s Life Science Ventures team invests in world-class companies in the areas of therapeutics, medical technology and diagnostics.

Life Science Ventures

A market driven investment strategy

Sunstone Life Science Ventures invests in early-stage Life Science companies in the therapeutic, medical technology and diagnostics fields. Our geographical scope is Europe with particular emphasis on the Nordic countries, Germany and Switzerland.

Our point of entry differs depending on the type of Life Science opportunity. In the therapeutic field, we invest when drug candidates are in the pre-clinical or clinical phase I.  In the areas of medical technology and diagnostics, we tend to invest in companies just before the pivotal clinical trials required to support the intended use and marketing claims.

Sunstone Life Science Ventures’ investment strategy has a strong industry focus vis-à-vis potential buyers of our portfolio companies. Since we believe that most exits in the Life Science sector will continue to take place in the M&A space, we prefer business models suitable for this exit route. To appear on potential acquirers’ radar screens, we invest in opportunities that have the potential of becoming either a threat or a complement to existing products on the market. We look out for opportunities which target unmet medical needs in commercially attractive markets, and we seek products which, once approved, are likely to receive attractive reimbursement and pricing structures. We have a preference for companies targeting niche markets. In the therapeutic area, opportunities aimed at specialty pharma and orphan drug indications are especially interesting, whereas we consider opportunities aimed at widespread diseases already addressed by established medical treatment regimes less interesting.

We believe that the single most important factor when developing a successful company is the quality of the management team. This is not the same as saying that we only invest in savvy entrepreneurs with a strong track record. But less experienced management teams should be open to change if needed to accelerate the company.

We are committed to working hands-on with our portfolio companies to build value. In most cases, Sunstone is represented on the board of directors and works closely with the management team and the board members to develop the company. Another unique offering aimed at building the value of our portfolio companies is Sunstone’s Business Development Board, established in 2007 and consisting of leading Life Science executives from Europe, the US, and Japan.

Headquartered in Copenhagen, Sunstone Capital is an early-stage Life Science and Technology venture capital company investing in European start-up companies with strong potential to achieve global success in their markets. Since our establishment in 2007, we have built a strong portfolio currently totaling 50 companies and have completed several successful trade sales and IPOs.

With approximately EUR 700 million in funds under management distributed on seven funds, Sunstone is today one of the leading and most active independent venture capital investors in the Nordic market.

Our limited partner investors currently include major Nordic and international institutional investors: European Investment Fund, Industriens Pension, Sampension, ATP, Nordea Liv og Pension, Vaekstfonden, and Dansk Vækstkapital.

Our origin – Vikings in the water
A sunstone is a gemstone that was used by the seafaring Vikings a thousand years ago as a navigational instrument to explore the world and find their way home again. Although probably not aware of it, the Nordic explorers and warriors were actually using advanced technology (downward wavelength conversion) to open up new markets and create new opportunities.

At Sunstone, we work with our companies to conquer the world and help them pave the road for a safe and prosperous return for our investors.

Sunstone’s Technology Ventures team invests in software, mobile and and internet companies with global potential.

Technology Ventures

Sunstone’s Life Science Ventures team invests in world-class companies in the areas of therapeutics, medical technology and diagnostics.

Life Science Ventures

A market driven investment strategy

Sunstone Life Science Ventures invests in early-stage Life Science companies in the therapeutic, medical technology and diagnostics fields. Our geographical scope is Europe with particular emphasis on the Nordic countries, Germany and Switzerland.

Our point of entry differs depending on the type of Life Science opportunity. In the therapeutic field, we invest when drug candidates are in the pre-clinical or clinical phase I.  In the areas of medical technology and diagnostics, we tend to invest in companies just before the pivotal clinical trials required to support the intended use and marketing claims.

Sunstone Life Science Ventures’ investment strategy has a strong industry focus vis-à-vis potential buyers of our portfolio companies. Since we believe that most exits in the Life Science sector will continue to take place in the M&A space, we prefer business models suitable for this exit route. To appear on potential acquirers’ radar screens, we invest in opportunities that have the potential of becoming either a threat or a complement to existing products on the market. We look out for opportunities which target unmet medical needs in commercially attractive markets, and we seek products which, once approved, are likely to receive attractive reimbursement and pricing structures. We have a preference for companies targeting niche markets. In the therapeutic area, opportunities aimed at specialty pharma and orphan drug indications are especially interesting, whereas we consider opportunities aimed at widespread diseases already addressed by established medical treatment regimes less interesting.

We believe that the single most important factor when developing a successful company is the quality of the management team. This is not the same as saying that we only invest in savvy entrepreneurs with a strong track record. But less experienced management teams should be open to change if needed to accelerate the company.

We are committed to working hands-on with our portfolio companies to build value. In most cases, Sunstone is represented on the board of directors and works closely with the management team and the board members to develop the company. Another unique offering aimed at building the value of our portfolio companies is Sunstone’s Business Development Board, established in 2007 and consisting of leading Life Science executives from Europe, the US, and Japan.

Annual & quarterly reports